Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome**Presented at the 50th Annual Meeting of The American Fertility Society, San Antonio, Texas, November 5 to 10, 1994.

1995 ◽  
Vol 64 (3) ◽  
pp. 568-572 ◽  
Author(s):  
Martin D. Keltz ◽  
Ervin E. Jones ◽  
Antoni J. Duleba ◽  
Tibor Polcz ◽  
Karen Kennedy ◽  
...  
Keyword(s):  
In Vitro Fertilization ◽  
Annual Meeting ◽  
Luteal Phase ◽  
San Antonio ◽  
Cyst Formation ◽  
Gonadotropin Releasing Hormone ◽  
Vitro Fertilization ◽  
Gonadotropin Releasing Hormone Agonist ◽  
American Fertility Society

scholarly journals Multiple-dose versus single-dose gonadotropin-releasing hormone agonist after first in vitro fertilization failure associated with luteal phase deficiency: A randomized controlled trial

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052092602 ◽  
Author(s):  
Danni Qu ◽  
Yuan Li
Keyword(s):  
Single Dose ◽  
In Vitro Fertilization ◽  
Luteal Phase ◽  
Multiple Dose ◽  
Dose Group ◽  
Gonadotropin Releasing Hormone ◽  
Vitro Fertilization ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Ivf Failure

Objective To evaluate the efficacy and safety of multiple- versus single-dose gonadotropin-releasing hormone agonist (GnRH-a) addition to luteal phase support (LPS), in patients with a first in vitro fertilization (IVF) failure associated with luteal phase deficiency (LPD). Methods Eighty patients with a first IVF failure associated with LPD were randomly assigned into single-dose and multiple-dose GnRH-a groups. In the second IVF attempt, patients in the single-dose group were given standard LPS plus a single dose of GnRH-a 6 days after oocyte retrieval. Patients in the multiple-dose group received standard LPS plus 14 daily injections of GnRH-a. Children conceived were followed up for 2 years. Results Pregnancy (67.5% vs. 42.5%), clinical pregnancy (50.0% vs. 22.5%), and live birth rates (42.5% vs. 20.0%) were significantly higher in the multiple-dose versus single-dose GnRH-a group. Patients in the multiple-dose GnRH-a group had significantly higher progesterone levels 14 days after oocyte recovery (35.9 vs. 21.4 ng/mL). No significant difference existed in the status at birth or developmental and behavior assessments of 2-year-old children conceived in both groups. Conclusions Daily addition of GnRH-a to standard LPS can achieve better pregnancy outcomes with a sustained safety profile in patients with a first IVF failure associated with LPD.

scholarly journals Luteal-phase support in assisted reproductive technology: An ongoing challenge

2021 ◽  
pp. 761-772
Author(s):  
Saeideh Dashti ◽  
Maryam Eftekhar
Keyword(s):  
In Vitro Fertilization ◽  
Assisted Reproductive Technology ◽  
Luteal Phase ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
Vitro Fertilization ◽  
Releasing Hormone ◽  
Luteal Phase Support ◽  
Gonadotropin Releasing Hormone Agonist

It has been shown that in controlled ovarian hyper stimulation cycles, defective luteal phase is common. There are many protocols for improving pregnancy outcomes in women undergoing fresh and frozen in vitro fertilization cycles. These approaches include progesterone supplements, human chorionic gonadotropin, estradiol, gonadotropin-releasing hormone agonist, and recombinant luteinizing hormone. The main challenge is luteal-phase support (LPS) in cycles with gonadotropin-releasing hormone agonist triggering. There is still controversy about the optimal component and time for starting LPS in assisted reproductive technology cycles. This review aims to summarize the various protocols suggested for LPS in in vitro fertilization cycles. Key words: Luteal-phase support, IVF, HCG, Progesterone, GnRH agonist, Recombinant LH.

Sign in / Sign up

Export Citation Format

Share Document